- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02934880
Impact of Adapted Physical Activity on Cognitive Functions in Breast Cancer (COG-SPORTIF)
Study of Impact of Adapted Physical Activity on Cognitive Functions and Quality of Life in Patients Treated for Locally Advanced Breast Cancer
Breast cancer is the most frequent cancer in women in western countries. The improvement of therapeutic management associated to the developement of supportive care allows patient to live longer in better conditions. But several studies have showed the deleterious impact of treatment such as chemotherapy on cognition. To limit these damages, non therapeutic approaches such as Adapted Physical Activity (APA) have been developped.
The goal of this study is to evaluate the benefit of APA program on cognitive functions in patients with locally advanced breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patient with cognitive complaint will be randomized in two groups :
- Experimental group : Immediate APA program (after randomization)
- Standard group : Delayed APA program (3 months after randomization)
APA program contains 10 sessions of APA within five weeks (twice a week). Each session is composed of 5 exercises (each made of 3 serial of 7 repetitions in slow speed).
A cognitive and quality of life assessments will occur in two groups at 3 and 6 months after randomization.
The primary objective of the study is to evaluate the impact of APA program on the improvement of cognitive functions in patients with breast cancer who have been treated by adjuvant chemotherapy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14076
- Centre Francois Baclesse
-
Lille, France, 59000
- Centre Oscar Lambret
-
Rouen, France, 76038
- Centre Henri Becquerel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women
- More than 18 years old
- Locally advanced breast cancer
- Patient who undergone surgery
- Cognitive complaint (FACT-COG inferior or equal to 8/16)
- No metastasis at the inclusion
- Patient who received adjuvant therapy by chemotherapy
- Patient with a social protection
- Barbizet scale Superior or equal to 3
- No neurological history
- No medical contraindication to APA
- Inform consent signed
Exclusion Criteria:
- Metastatic breast cancer
- History of other cancer (in 5 years before inclusion)
- Current chemotherapy or radiotherapy
- Chemotherapy or radiotherapy ended for more than 6 months
- Current APA program
- Blood transfusion for less than 6 mois
- Minimal mental score inferior to normal
- Patient no able to respond to the cognitive test
- Patient no able to realize APA program
- Drug use
- Alcohol abuse
- Patient Under guardianship or curatorship or deprived of liberty
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Immediate APA
intervention: 10 sessions of APA within the 5 weeks (2 sessions per week) following the randomization
|
10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
|
|
Active Comparator: Delayed APA
intervention: 10 sessions of APA in 5 weeks (2 sessions per week) , 3 months after randomization
|
10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
proportion of patient with an increase of Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG) result
Time Frame: After APA program
|
Proportion of patient with an increase superior or equal to seven points between FACT-COG at the inclusion and FACT-COG after APA program
|
After APA program
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improval of quality of life
Time Frame: After APA program
|
Impact of APA on quality of life (FACT-B result)
|
After APA program
|
|
Comparison of immediate APA and delayed APA on quality of life
Time Frame: 30 months
|
Comparison between FACT-B, FACT-COG and FACIT-F results in the two groups
|
30 months
|
|
Study of relations between cognitive functions and quality pf life
Time Frame: After APA program
|
Correlation between patient questionnaire and data of psychological tests done by neuropsychologist
|
After APA program
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Olivier Rigal, MD, Centre Henri Becquerel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHB16.01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on immediate APA program
-
GERCOR - Multidisciplinary Oncology Cooperative...Active, not recruitingMetastatic Pancreatic Cancer | Unresectable Locally Advanced CancerFrance
-
Centre Hospitalier Universitaire de BesanconGERCOR - Multidisciplinary Oncology Cooperative GroupRecruiting
-
Centre Antoine LacassagneCentre Hospitalier Universitaire de NiceNot yet recruitingBreast Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Ovarian AdenocarcinomaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruiting
-
University of BarcelonaCatSalut Catalonia, SpainCompletedCardiovascular Risk | Obesity Prevention | Non-communicable Diseases (NCD)Spain
-
University Hospital, RouenTerminated
-
Centre Hospitalier Universitaire de Saint EtienneRecruitingChronic Fatigue SyndromeFrance
-
Fondation Santé des Étudiants de FranceRecruiting
-
Western University, CanadaCanadian Institutes of Health Research (CIHR); Public Health Agency of Canada...CompletedObesity | OverweightCanada, United States
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineRecruitingAnxiety | Hematological Malignancies | Relaxation | Adapted Physical ActivityFrance